Evidence that chorion-decidual prolactin release is calcium dependent

The effects of L-arginine on the release of prolactin from decidual explants in vitro

OBJECTIVE

Our aim was to elucidate a role for the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway in the control of decidual prolactin release in vitro.

STUDY DESIGN

In decidua obtained from normal vaginal deliveries, we examined the effects of L -arginine; a stable analog of cyclic guanosine monophosphate, 8-bromo-cyclic guanosine monophosphate; and two nitric oxide synthase inhibitors, L -nitro arginine methyl ester (L -NAME) and L -nitro monomethyl arginine (L -NMMA) on the release of prolactin from decidual tissue in vitro.

RESULTS

L -arginine, at 100 micromol/L, produced an increase in medium prolactin concentration after a 2-hour exposure; however, its inactive isomer, D -arginine, at the same concentration, did not. The increase in prolactin release initiated by L -arginine was sustained after a 24-hour incubation. In addition, 8-bromo-cyclic guanosine monophosphate (10 micromol/L) stimulated prolactin release. At 2 hours, the effects of L -arginine were reversed by L -NAME (100 micromol/L), which by itself was without effect. Incubation of tissue with L -NAME for 24 hours inhibited prolactin secretion (24 hours; P <.05, vs control); however, L -NMMA was without effect.

CONCLUSIONS

These results suggest that the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway is involved in the regulation of prolactin secretion by decidual tissue.

Long-term effects of calcium availability on prolactin and protein synthesis in human decidual cells

Ever since decidual cells were recognized as the source of decidual prolactin (dPRL), very few reports have dealt with the role of calcium (Ca2+) on dPRL synthesis and release. In a recent work, we described the presence of T-type Ca2+ channels in these cells, giving Ca(2+)-dependent action potentials. However, we failed to demonstrate any action of decidual cell Ca2+ modulation on acute dPRL release, but observed only long-term effects. We have now investigated these effects on decidual protein and dPRL synthesis after 24 h treatments. When Ca2+ channel blockers or EGTA (2 mM) were added to the culture medium, dPRL release and [3H] leucine incorporation into proteins decreased. Increasing external Ca2+ up to 2 mM instead of 0.8 mM or changing the external K+ concentration (30 mM instead of 5.6) had no consequence on dPRL release, whereas 2 mM of Ca2+ enhanced total protein synthesis. No toxicity was noted with these treatments. Finally a possible effect of Ca2+ modulation on dPRL synthesis was studied using [35S] methionine. The specific activity of [35S] methionine on dPRL was similar in control and treated cells (EGTA, 2 mM Ca2+, cobalt). These results support the idea that Ca2+ controls dPRL synthesis in decidual cells, acting only on general protein synthesis processes.

Prolactin and related peptides in pregnancy

This brief review has attempted to portray the complex involvement of prolactin in pregnancy. Pituitary prolactin production and lactotroph proliferation are markedly affected by oestrogens and pregnancy. Enlargement of pre-existing prolactinomas may occur during pregnancy induced with dopamine agonist drugs, and this can be a major clinical problem with larger tumours. Prolactin is produced by late luteal and decidualized endometrium as well as by the pituitary gland, but much less is known about its secretory regulation or its function. The family of prolactin-related protein hormones is rapidly expanding with the recognition of placental lactogens, variant growth hormone, proliferin, decidual luteotropin, and at least two further prolactin-related peptides in rodents. This complex system of related but distinct protein hormones, with different temporal patterns of production during gestation, suggests an important physiological role, but it remains to be seen to what extent they are involved in placental function itself, maternal metabolism or fetal growth.

Drug-induced changes in prolactin secretion. Clinical implications

Prolactin secretion is affected by various diseases as well as by many drugs in humans and animals. While marked hyperprolactinaemia suggests the presence of a pituitary tumor, moderate changes may also occur in various endocrine or non-endocrine disorders. Drugs can interfere with prolactin regulation via complex mechanisms at the hypothalamus or at the pituitary site, but possible changes in prolactin metabolism are poorly understood as yet. This survey of the literature up to June 1986 covers the influence of various groups of drugs and agents on the plasma prolactin level under various conditions. It contains information that will facilitate evaluation of whether hyper- or hypoprolactinaemia may result from therapeutic intervention or must be related to an underlying disease. It is obvious that more subtle changes can be revealed by the use of dynamic tests either to stimulate or to suppress prolactin secretion.

Cyclic AMP inhibits the synthesis and release of prolactin from human decidual cells

Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%. Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. Dibutyryl cAMP, IBMX, and cholera toxin, however, had no effect on the release of 35S-methionyl-prolactin from decidual cells preincubated for 24 h in medium with 35S-methionine. These agents, however, had no effects on the synthesis or release of TCA-precipitable 35S-decidual proteins and did not cause the degradation of intracellular or released prolactin. The demonstration that agents which increase intracellular cAMP levels inhibit the synthesis and release of decidual prolactin strongly implicates cAMP as a second messenger in the regulation of the synthesis and release of the hormone. The inhibitory effect of cAMP on prolactin release appears to be on the release from a rapidly releasable, newly synthesized intracellular prolactin pool.

Immunohistochemical identification of prolactin and 24K protein in secretory endometrium

Inadequate endometrial differentiation is a cause of infertility and recurrent pregnancy loss. Diagnostic histologic dating criteria may be supplemented by the immunohistochemical identification of protein markers in late secretory endometrium. Late secretory endometrium has been shown to contain prolactin. The authors report the immunohistochemical localization of prolactin and 24K protein in late secretory endometrium using monoclonal antisera and the dinitrophenyl hapten sandwich-staining technique. The appearance of these proteins in decidualized stromal cells of late secretory endometrium may provide a more specific indicator of endometrial development and differentiation, if their late appearance or absence can be correlated with pregnancy wastage.

Different subcellular storage sites for decidual- and pituitary-derived prolactin: possible explanation for differences in regulation

The intracellular sites of storage for human decidual- and pituitary-derived prolactins have been determined by measuring the hormones in subcellular fractions following differential and density gradient centrifugations. In decidual tissue, 78 +/- 4% (mean +/- SE, n = 5) of the prolactin was detected in the post-microsomal supernatant, while 98% of the prolactin in the pituitary was detected in mitochondrial and microsomal particulate fractions. Following centrifugation on sucrose density gradients, decidual prolactin was distributed diffusely throughout the gradients, while greater than 90% of the pituitary prolactin sedimented as a single peak with a mean density of 1.22 g/cm3. These studies indicate that, unlike pituitary prolactin, decidual prolactin is not stored in secretory granules. Differences in the intracellular storage sites of decidual and pituitary prolactins may explain observed differences in the regulation of prolactin secretion by decidual and pituitary tissues.